NCT07320950 2026-01-06
Neuroprotective Effect of Neurotropin on Chronic OXA-induced Neurotoxicity in Stage II and Stage III CRC Patients
Sun Yat-sen University
Phase 3 Completed
Clinical Trials
11 trialsNCT05025826 2025-12-02
PROPERTY
Nantes University Hospital
Phase NA Active not recruiting
NCT05798884 2023-04-05
Electro-acupuncture for the Prevention and Treatment of Oxaliplatin-induced Neurotoxicity in Colorectal Cancer Patients
Hong Kong Baptist University
Phase NA Unknown
NCT01279681 2017-12-08
Combination Chemotherapy Plus Bevacizumab With or Without Oxaliplatin in Treating Older Patients With Metastatic Colorectal Cancer
Alliance for Clinical Trials in Oncology
Phase 3 Terminated
NCT03330964 2017-11-06
Clinical Trial of Electroacupuncture Stimulation on Prevention and Treatment of Oxaliplatin Neurotoxicity
The First Affiliated Hospital of Dalian Medical University
Phase NA Unknown
NCT00316914 2016-08-11
Calcium Gluconate and Magnesium Sulfate in Preventing Neurotoxicity Caused By Oxaliplatin in Patients Receiving Combination Chemotherapy for Stage II, Stage III, or Stage IV Colorectal Cancer That Has Been Completely Removed By Surgery
Alliance for Clinical Trials in Oncology
Phase 3 Completed
NCT00305188 2016-05-04
Evaluation of the Efficacy of Xaliproden (SR57746A) in Preventing the Neurotoxicity of Oxaliplatin / 5FU/LV Chemotherapy.
Sanofi
Phase 3 Completed
NCT02024438 2015-09-28
Monosialotetrahexosylganglioside Sodium Injection for Prevention Neurotoxicity of mFOLFOX 6 in Advanced Gastric Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 3 Unknown
NCT00274885 2011-12-05
Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal Cancer
National Cancer Institute (NCI)
Phase 4 Unknown
NCT00884767 2009-07-08
Biomarkers in Predicting Neurotoxicity in Patients With Colorectal Cancer Receiving Oxaliplatin
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00272051 2006-09-13
XENOX - Evaluation of the Efficacy of Xaliproden in Reducing the Neurotoxicity of the Oxaliplatin + 5-FU/LV Chemotherapy
Sanofi
Phase 3 Completed